A Multiple Ascending Dose Study of ETC-1002 in Healthy Subjects
NCT ID: NCT01485146
Last Updated: 2019-03-28
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE1
24 participants
INTERVENTIONAL
2011-10-25
2012-01-25
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Single Ascending Dose Trial to Evaluate the Safety, Tolerability, PK, and PD of MT1002 for Injection
NCT04116840
A Study to Assess the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Pharmacodynamics of E2025 in Healthy Participants
NCT05726851
A Study of Single Ascending Doses of STAR-101 in Healthy Participants
NCT04081597
Study Evaluating the Safety and Pharmacokinetics of Ascending Single IV Doses of ERB-257
NCT00722501
A Dose Escalation Study to Assess the Safety, Tolerability, and Pharmacokinetics of ASP2408 Following Single Intravenous Doses in Healthy Subjects
NCT02125435
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
SINGLE_GROUP
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Cohort 1
8 Healthy Subjects in Phase I Unit
ETC-1002
escalating doses
Cohort 2
8 Healthy Subjects in Phase I Unit
ETC-1002
escalating doses
Cohort 3
8 Healthy Subjects in Phase I Unit
ETC-1002
escalating doses
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
ETC-1002
escalating doses
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Body Mass Index of 18-32 kg/m2 inclusive with body weight \>50 kg
Exclusion Criteria
* Clinically significant disease that requires a physician's care and/or would interfere with study evaluations
* History of drug or alcohol abuse, consumption of alcohol within 48 hours prior to randomization, or a positive test for alcohol or drugs with a high potential for abuse prior to randomization
* Use of any prescription or nonprescription drugs, vitamins, or dietary supplements within 14 days prior to randomization
18 Years
60 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Esperion Therapeutics, Inc.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Narendra Lalwani, PhD
Role: STUDY_DIRECTOR
Esperion Therapeutics, Inc.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Jasper Clinic, Inc.
Kalamazoo, Michigan, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
ETC-1002-004
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.